Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Carcinoma, Hepatocellular 5Prostatic Neoplasms 3Liver Neoplasms 3Kidney Neoplasms 3Head and Neck Neoplasms 2Thyroid Neoplasms 1Sleep Apnea, Obstructive 1Sarcoma 1Rhinitis, Allergic, Seasonal 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Fibrosis 1Pulmonary Embolism 1Pulmonary Disease, Chronic Obstructive 1Ovarian Neoplasms 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Hypertension, Pulmonary 1Emphysema 1Cystic Fibrosis 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Bronchiectasis 1Asthma 1Asbestosis 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × perflutren × Clear all
NCT01062178 2016-03-08

Efficacy of Ultrasound Contrast Agent to Assess Renal Masses

University Health Network, Toronto

Phase 2 Completed
167 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡